Kevin Richardson
Corporate Officer/Principal chez TELIX PHARMACEUTICALS LIMITED
Profil
Kevin Richardson is currently the Chief Executive Officer-Americas at Telix Pharmaceuticals Ltd.
and a Director at Telix QSAM, Inc. He previously served as the Chief Executive Officer-Americas Region at Sirtex Medical Pty Ltd.
from 2016 to 2017 and as the Chief Operating Officer & Director at Uroshape LLC.
Postes actifs de Kevin Richardson
Sociétés | Poste | Début |
---|---|---|
TELIX PHARMACEUTICALS LIMITED | Corporate Officer/Principal | 01/07/2022 |
Anciens postes connus de Kevin Richardson
Sociétés | Poste | Fin |
---|---|---|
SIRTEX MEDICAL LIMITED | Corporate Officer/Principal | 18/05/2017 |
Uroshape LLC
Uroshape LLC Medical SpecialtiesHealth Technology Uroshape LLC is a private company that manufactures and supplies medical equipment. The company is based in Melbourne, FL. The CEO of the company is Ralph Zipper. | Directeur des opérations | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 3 |
---|---|
Sirtex Medical Pty Ltd.
Sirtex Medical Pty Ltd. Miscellaneous Commercial ServicesCommercial Services Sirtex Medical Ltd. manufactures, and distributes liver cancer treatments. It operates through the following geographical segments: Asia Pacific, Americas, and Europe, Middle East, and Africa. It offers targeted radiation therapy known as SIR Spheres Y-90 resin microspheres. The company was founded in 1997 and is headquartered in St Leonards, Australia. | Commercial Services |
Uroshape LLC
Uroshape LLC Medical SpecialtiesHealth Technology Uroshape LLC is a private company that manufactures and supplies medical equipment. The company is based in Melbourne, FL. The CEO of the company is Ralph Zipper. | Health Technology |
Telix Pharmaceuticals Ltd.
Telix Pharmaceuticals Ltd. BiotechnologyHealth Technology Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia. | Health Technology |